References
- European Pharmacopoeia. (2005). Chewing gums medicated. Strasbourg: European Department for the Quality of Medicines within the Council of Europe. Supplement 5.2. 5th edition. 3136–3137.
- Barabolak R, Hoerman K, Kroll B, Record D. (1991). Gum chewing profiles in the U.S. population. Community Dent Oral Epidemiol, 19:125–126.
- Mathias NR, Hussain MA. (2010). Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci, 99:1–20.
- Christrup LL, Bonde J, Rasmussen SN, Rassing MR. (1990). Relative bioavailability of (+/-)-verapamil hydrochloride administered in tablets and chewing gum. Acta Pharm Nord, 2:371–376.
- Grabnar I, Maggi L, Cocchietto M, Conte U, Voinovich D. (2007). Bioavailability of metoclopramide from a new chewing gum device. J Drug Deliv Sci Tech, 17:173–176.
- Kamimori GH, Karyekar CS, Otterstetter R, Cox DS, Balkin TJ, Belenky GL et al. (2002). The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int J Pharm, 234:159–167.
- Noehr-Jensen L, Damkier P, Bidstrup TB, Pedersen RS, Nielsen F, Brosen K. (2006). The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers. Eur J Clin Pharmacol, 62:437–445.
- Chaudhary SA, Shahiwala AF. (2010). Medicated chewing gum–a potential drug delivery system. Expert Opin Drug Deliv, 7:871–885.
- Eisenstadt B, Cash PA, Bakal AI. (1998). Chewing gum containing cough suppressing agent. U.S. patent 5, 846, 557, 8 Dic.
- Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP. (2005). Chewing gum of antimicrobial decapeptide (KSL) as a sustained antiplaque agent: preformulation study. J Control Release, 107:122–130.
- Testa ES. (1999). Medicated chewing gum and a process for preparation thereof. U.S. Patent 5, 866, 179, 2 Feb.
- Maggi L, Segale L, Conti S, Ochoa Machiste E, Salini A, Conte U. (2005). Preparation and evaluation of release characteristics of 3TabGum, a novel chewing device. Eur J Pharm Sci, 24:487–493.
- Suleiman MS, Najib NM, el-Sayed YM, Badwan A. (1989). Stability-indicating high-performance liquid chromatographic assay for the determination of metoclopramide hydrochloride in pharmaceutical dosage forms. Analyst, 114:365–368.
- Ciurba A, Popovici A. (2005). Stability at various temperatures of sodium diclofenac gelatin capsules. Revista de Medicina si Farmacie, 49:150–152.
- Kubala T, Gambhir B, Borst SI. (1993). A specific stability indicating HPLC method to determine diclofenac sodium in raw materials and pharmaceutical solid dosage forms. Drug Dev Ind Pharm, 19:749–757.
- Fairbrother JE. (1974). Acetaminophen.. In: Florey K, editor. Analytical Profiles of Drug Substances. Vol. 3. New York: Academic Press, 1–109.
- Jamil S, Talegaonkar S, Khar RK, Kohli K. (2008). Development and validation of a stability-indicating LC method for simultaneous analysis of aceclofenac and paracetamol in conventional tablets and in microsphere formulations. Chromatographia, 68:557–565.
- Asker AF, Harris CW. (1990). Influence of storage under tropical conditions on the stability and dissolution of ascorbic acid tablets. Drug Dev Ind Pharm, 16:165–174.
- Hajratwala BR. (1985). Stability of ascorbic acid. S.T.P. Pharma 1:281–286.
- Kelly CA. (1970). Determination of the decomposition of aspirin. J Pharm Sci, 59:1053–1079.
- British Pharmacopoeia. (2005). Sodium picosulfate, oral powder. London: The stationery Office on Behalf of the Medicines and Heathcare Products Regulatory Agency (MHRA), 2799.
- United State Pharmacopoeia and National Formulary (USP 31-NF 25). (2008). US Pharmacopeia Convention. Rockville.
- International Conference on Harmonisation. (2009). Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1F/Stability_Guideline_WHO.pdf
- Gajendran J, Kraemer J, Knudsen SR. (2008). Product performance test for medicated chewing gums. Pharmacopeial Forum, 34:843–847.
- Mroso PV, Li Wan Po A, Irwin WJ. (1982). Solid-state stability of aspirin in the presence of excipients: kinetic interpretation, modeling, and prediction. J Pharm Sci, 71:1096–1101.
- Zoglio MA, Maulding HV, Haller RM, Briggen S. (1968). Pharmaceutical heterogeneous systems. 3. Inhibition of stearate lubricant induced degradation of aspirin by the use of certain organic acids. J Pharm Sci, 57:1877–1880.
- Siepmann J, Peppas NA. (2001). Mathematical modeling of controlled drug delivery. Adv Drug Deliv Rev, 48:137–138.
- Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP. (2007). Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity. Pharm Res, 24:1544–1550.